Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
09/2005
09/22/2005WO2004060376A8 The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
09/22/2005US20050209466 Reproducible; avoids use of 3-pyrrolidinol as a starting material
09/22/2005US20050209465 By reacting with substituted acetylenes in the presence of a phosphine ligand and a base (K2CO3); used to make drugs
09/22/2005US20050209456 Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents
09/22/2005US20050209452 Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
09/22/2005US20050209302 Glycogen synthase kinase (GSK-3) inhibitors; diabetes, neurodegenerative diseases, stroke, neurotraumatic injuries and bipolar disorders; 5-acetyl-3-[3-(methoxycarbonylpropylamino)-(benzo-[1.3]dioxyo-5-yl)-methylidene]-2-indolinone for example
09/22/2005US20050209287 3-thio-4,5-disubstituted-4H-1,2,4-triazoles; Inhibiting RNase H activity, and RNA dependent DNA polymerase (RDDP) activity of HIV reverse transcriptase; 4-benzyl-3-(benzylthio)-5-(2-furyl)-4H-1,2,4-triazole for example; retrovirus-associated cancer; drug screeening
09/22/2005US20050209285 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs
09/22/2005US20050209284 Tec kinase inhibitors
09/22/2005US20050209282 Inhibitors of voltage-gated sodium channels; acute, chronic, neuropathic, or inflammatory pain such as femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; neuropathic low back pain; myofascial pain syndrome; fibromyalgia
09/22/2005US20050209280 Diagnostic agent, method for detecting a carcinoma, and means for the treatment thereof
09/22/2005US20050209278 Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
09/22/2005US20050209277 Such as N'-(1H-benzimidazol-2-ylmethyl)-N'-5,6,7,8-tetrahydroquinolin-8-yl-1,4-butanediamine; making chemokine receptor (CXCR4) antagonists useful as HIV antivirals; reacting a 5,6,7,8-tetrahydroquinolinylamine with an alkyl aldehyde bearing a phthalimide or a di-tert-butoxycarbonyl protecting group
09/22/2005US20050209276 Etherification, dehalogenation; filtration, crystallization; bactericides
09/22/2005US20050209275 Beta 2-adrenergic receptor agonists
09/22/2005US20050209273 Neuroprotectants, analgesics or anticonvulsants
09/22/2005US20050209261 Rho-kinase inhibitors
09/22/2005US20050209254 Kinesin spindle protein (KSP) inhibitors; 2-substituted 4-(thio)oxo-3,4-dihydroquinazolines; use in combination with other anticancer agents
09/22/2005US20050209249 Use as antidiabetic agents, treating hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis; (3S, 5S)-4-([5-(Thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-sulfamoyl)-benzoic acid for example
09/22/2005US20050209247 Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors
09/22/2005US20050209244 N{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
09/22/2005US20050209240 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors
09/22/2005US20050209232 Useful for treating inflammatory, immunological, and integrin-mediated disorders such as inflammatory bowel disease; 2-(3,3-Diisopropyl-ureido)-3-[4-(5-methoxy-2-methyl-3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-propionic acid for example
09/22/2005US20050209230 2,4-Pyrimidinediamine compounds and their uses
09/22/2005US20050209225 Substituted indoles and their use as integrin antagonists
09/22/2005US20050209223 N-(p-(substituted 1,2,3-triazol-1-yl)phenyl) derivatives of cycloazaalkanes; particularly useful for treating methicillin-resistant Staphylococcus aureas infections
09/22/2005US20050209217 3-Mercaptopyrrolidines as farnesyl protein transferase inhibitors
09/22/2005US20050209216 Inhibit the synthesis of TNF-alpha (TNF=tumor necrosis factor); use treating diseases linked to immune and inflammatory disorders or as analgesics; e.g. 7-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)quinoline
09/22/2005US20050209213 Quinoline compound
09/22/2005US20050209197 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds
09/22/2005US20050209195 Derivatives of compound 1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl)methylene]-2H-indol-2-one; Antitumor agents; tyrosine kinase inhibitors
09/22/2005US20050209106 Herbicides; selectively controlling broad-leaved weeds and weed grasses in crops of useful plants; 6-ethyl-4-(4-trifluoromethyl-1H-1-pyrazolyl)-2-(2-trifluoromethylpyridin-4-yloxy)pyrimidine
09/22/2005US20050208582 Pyrazole compounds and pharmaceutical compositions comprising the compound
09/22/2005US20050207996 Use of osteopontin in dental formulations
09/22/2005DE102004010254A1 New 4-heterocyclyl-1-acyl-piperidine derivatives, useful e.g. for treating headache, diabetes and cardiovascular disease, are antagonists of calcitonin-gene related peptide
09/22/2005CA2560111A1 Aminophenylpropanoic acid derivative
09/22/2005CA2560098A1 2-aminoquinazoline derivative
09/22/2005CA2559507A1 Compounds, compositions and methods for inhibiting or treating hiv-1
09/22/2005CA2559143A1 Novel cycloalkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
09/22/2005CA2559139A1 Novel alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
09/22/2005CA2558893A1 Vla-4 antagonists
09/22/2005CA2558552A1 Sulphonylpyrroles as hdac inhibitors
09/22/2005CA2558391A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
09/22/2005CA2558243A1 Inhibitors of histone deacetylase
09/22/2005CA2558224A1 Ion channel modulators
09/22/2005CA2558217A1 Ion channel modulators
09/22/2005CA2558214A1 Ion channel modulators
09/22/2005CA2557904A1 Hiv integrase inhibitors
09/22/2005CA2557672A1 Ion channel modulators
09/22/2005CA2557665A1 Ion channel modulators
09/22/2005CA2557648A1 Ion channel modulators
09/22/2005CA2557642A1 Ion channel modulators
09/22/2005CA2557527A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
09/22/2005CA2557247A1 Compounds as inhibitors of hepatitis c virus ns3 serine protease
09/22/2005CA2555867A1 Arylalkylamino-substituted quinazoline analogues
09/21/2005EP1577309A1 Optically active dihydropyridine derivative
09/21/2005EP1577302A1 Novel ethylenediamine derivatives
09/21/2005EP1577301A1 Diamine derivatives
09/21/2005EP1577298A1 Process for determining the purity of amlodipine
09/21/2005EP1577296A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their use
09/21/2005EP1577295A1 Process for preparing 2-oxo-1-pyrrolidine derivatives as intermediates
09/21/2005EP1576159A1 The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
09/21/2005EP1575963A1 Therapeutic agents
09/21/2005EP1575951A1 Heterocyclic compounds, methods of making them and their use in therapy
09/21/2005EP1575941A2 Process for preparing (s)-pantoprazole
09/21/2005EP1575940A1 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
09/21/2005EP1575939A1 Novel compounds having selective inhibiting effect at gsk3
09/21/2005EP1575938A1 Novel compounds having selective inhibiting effect at gsk3
09/21/2005EP1575937A2 Rabeprazole calcium
09/21/2005EP1575936A1 Complexes of e-2-methoxy-n-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
09/21/2005EP1575935A1 Process for the preparation of sulphinyl derivatives by oxidation of the corresponding sulfides
09/21/2005EP1575934A1 Carbazole derivatives and their use as npy-5 antagonists
09/21/2005EP1575926A1 New pyridazin-3(2h)-one derivatives
09/21/2005EP1575925A1 Novel carboxamides, the production and use thereof as medicaments
09/21/2005EP1575919A1 Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
09/21/2005EP1575918A2 Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
09/21/2005EP1575592A1 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
09/21/2005EP1575495A2 Compounds and methods
09/21/2005EP1575493A2 Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
09/21/2005EP1575486A2 Method and compositions for identifying anti-hiv therapeutic compounds
09/21/2005EP1395573B1 Method for separating methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidine- carboxylate -racemate
09/21/2005EP1299382B1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
09/21/2005EP1282602B1 Propanoic acid derivatives as integrin receptor antagonists
09/21/2005EP1265862B1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
09/21/2005EP1137640B1 Cyclic hydrazine derivatives as tnf-alpha inhibitors
09/21/2005CN1671717A Azole derivatives as antifungal agents
09/21/2005CN1671711A Calcitonin gene related peptide receptor antagonists
09/21/2005CN1671703A Method for preparing fused oxazinones from ortho-amino aromatic carboxylic acid and a carboxylic acid in the presence of a sulfonyl chloride and pyridine
09/21/2005CN1671702A Pyridines and pyrimidines substituted by 4-trifluoromethylpyrazolyl
09/21/2005CN1671700A Substituted alkylamine derivatives and methods of use
09/21/2005CN1671698A 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines
09/21/2005CN1671697A Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
09/21/2005CN1671696A 激酶抑制剂 Kinase inhibitors
09/21/2005CN1671695A Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors
09/21/2005CN1671694A Bisindolyl-maleimid derivatives as kinase inhibitors
09/21/2005CN1671693A Process for preparing indolinone derivatives
09/21/2005CN1671692A Method for producing highly pure hydroxy indolyl glyoxylic acid amides
09/21/2005CN1671691A Salt of (s)-pantoprazole and its hydrates
09/21/2005CN1671690A Antimicrobial aza-bicyclic derivates, their compositions and uses
09/21/2005CN1671689A Pyridyl-triazine derivatives as microbicidal active substances
1 ... 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 ... 1080